Antiviral therapies with phospholipase D inhibitors

摘要

Disclosed are methods of treating viral infections comprising, in one aspect, administering compounds that are phospholipase D inhibitors. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to antiviral therapies. For example, compounds having Phospholipase D activity (e.g., isoform selective Phospholipase D inhibitors) can be useful in antiviral therapies (e.g., influenza treatments).

主权项

1. A method for treating a subject comprising the step of co-administering an effective amount of a combination of two or more therapeutic agents to the subject;
wherein the subject has been diagnosed with a need for treatment of an influenza infection prior to the administering step; and wherein the combination of two or more therapeutic agents comprises: (a) an phospholipase D inhibitor; and (b) one or more therapeutic agents selected from: (i) a viral protein M2 ion channel inhibitor, (ii) a neuraminidase inhibitor, and (iii) a nucleoside analog selected from ribavirin, viramidine, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, 2′-deoxy-2′-fluoroguanosine, pyrazofurin, carbodine, and cyclopenenyl cytosine; wherein the phospholipase D inhibitor is a compound having a structure represented by a formula: Wherein R21 is a phenyl or halophenyl; each of R27 and R28 is, independently, a hydrogen or a C1 to C6 alkyl; R30 is an optionally substituted organic residue selected from aryl and heteroaryl, wherein the organic residue is up to C16, or a pharmaceutically acceptable salt thereof.